@DrMakaryFDA@US_FDA Dr. Makary, LERONLIMAB is inexpensive, very safe, readily available and with the MOA inhibiting the CCR5 receptor is prime to address multiple indications. What's not to like?π€·
@DrMakaryFDA Sir, I just saw you on CNBC discussing speeding up the consideration of innovative drugs with no adverse reactions. I am sure that you have heard of LERONLIMAB by CytoDyn. This monoclonal antibody has shown DRAMATIC RESULTS along with NO SAFETY ISSUES. WHY NOT???π€·
@AlbaDocherty@NIH THE solution, Leronlimab, is discussed at 11:18 in the Ted Talk. It has always been there for us, with an incredible safety profile, to boot.......
@johnmellencamp Sir, please get your daughter on the drug Leronlimab via an Emergency Investigational New Drug (EIND) application with the FDA. Is VERY PROMISING in cancer AND has little/no side effects. Please call CEO Dr. Jacob Lalezari at Cytodyn at 360-980-8524. Good luck!
@charliesheen@lilpump Hi Charlie, Mike here. I read an article about you today on RadarOnline. Are you still taking Pro 140, and are you a shareholder of Cytodyn stock? From an advocate of Leronlimab and a longtime shareholder.π
@athersys Was anything mentioned about the pps dropping almost 50% since the R.S.? Hmmmm, glad I supported the company's argument to support the R.S., as a result, do you happen to now have a couch that I can sleep on?
@athersys yup, and insiders have enriched themselves disproportionately to actual milestones achieved along the way. Almost 100% funded on the backs of common shareholders. When are you going to show ME the money? You know, the guy (all shareholders) who made whatever progress possible.